Bioavailability of bromazepam in man after single administration of an oral solution.

The relative bioavailability of a liquid oral form of 7-bromo-1,3-dihydro-5-(2-pyridyl)-2H-1,4-benzodiazepin-2-one (bromazepam, Lexotan, Lexotanil) in comparison with the conventional oral form (capsules) was investigated. The study was performed on six healthy volunteers who were administered both the drug products in a single oral dose of 3 mg of bromazepam in a randomized cross-over trial. An additional investigation was performed on the same subjects by administering the liquid oral solution at a lower dosage: 1.5 mg in order to confirm first-order kinetics at low dosage, too. The results showed the same bioavailability for the oral forms tested and confirmed first-order kinetics for the 1.5 mg dose, too.